Wolverine Legal Status, FDA 503A Category, and Compounding Access

Where Wolverine legal status stands today — and where it is heading

Before any of the science, the terminal reads the regulatory packet, because that is what the "legit" question turns on. The Wolverine legal status picture has genuine forward momentum: access to its component peptides is under active FDA review and may expand in 2026. Anchoring that momentum is one concrete, scheduled fact — the FDA's Pharmacy Compounding Advisory Committee (PCAC) is set to meet on July 23-24, 2026 to discuss these peptides as candidates for the Section 503A Bulks List ^[10]. That is the honest leading edge of the story, and it is a scheduled discussion, not a decision.

The present-tense fact has to be stated plainly alongside it. Both of Wolverine's components are currently classified by the FDA as 503A "Category 2" bulk drug substances — substances FDA identified as ones that may present significant safety risks — effective with the FDA's September 29, 2023 update to the list of nominated substances ^[9]. Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1, which means compounding access to these peptides is currently restricted. Neither peptide is an FDA-approved drug, and the blend has no approved indication ^[9].

So two things are true at once. The current category is restrictive; the trajectory is open. The blend's WADA prohibition status is covered below, and none of what follows is medical or legal advice — it is general information about the regulatory landscape.

What 503A Category 2 means for both constituents

Under the U.S. Federal Food, Drug, and Cosmetic Act, drug compounding runs through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight ^[9]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; substances not yet listed are evaluated by FDA through a public nomination process with input from PCAC ^[9].

Within that framework, FDA's interim policy sorted nominated substances into Category 1 (covered by enforcement discretion while under evaluation) and Category 2 (identified as raising significant safety risks, and not covered by that discretion) ^[9]. Both of Wolverine's components sit in Category 2 today, with no constituent carve-out. BPC-157 — evaluated as "BPC-157 (free base)" and "BPC-157 acetate" — is in Category 2 for 503A compounding, effective with the September 29, 2023 list update, with FDA citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization ^[9]. TB-500 — listed by FDA as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — is in Category 2 for 503A compounding, effective with the same September 29, 2023 update, with FDA citing concerns including potential immunogenicity for certain routes and a lack of important safety information ^[9]. FDA's own list entry establishes the relationship between the marketed name and the fragment: TB-500 is the LKKTETQ fragment associated with Thymosin Beta-4 ^[9].

The July 2026 advisory-committee review

Both components are on the published agenda of the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026, listed as bulk drug substances "being considered for inclusion on the 503A Bulks List" ^[10]. There is no carve-out: BPC-157 and TB-500 are both currently Category 2 and both are under this one scheduled review.

What that meeting is, precisely: a scheduled, advisory discussion of substances under evaluation. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by PCAC — being discussed by the committee is a step in evaluation, not a final listing decision ^[9]. The outcome of the July 23-24, 2026 meeting is not known, and nothing on this page should be read as asserting a reclassification, a listing, or a removal as already done, dated, or certain. The review is genuine and the date is real; the result is still ahead.

How legally compounded peptide access works

In the U.S., a legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is appropriate and issues a valid, patient-specific prescription ^[9]. The preparation is then made either by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, by an FDA-registered 503B outsourcing facility ^[9]. Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription issued — it is a route to a licensed-prescriber consultation, not a separate legal status, and it does not change which substances are eligible to be compounded ^[9].

The eligibility caveat is the part that currently binds for these peptides. A compounder may use a requested active ingredient only if that ingredient is permitted under the 503A/503B bulk-substance rules; ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands ^[9]. As long as BPC-157 and TB-500 remain in Category 2, that is the operative constraint. This is general information about how the pathway works — not a route to obtain a restricted substance, and not medical or legal advice.

Is Wolverine legal?

Neither constituent is an FDA-approved drug and the blend has no approved therapeutic indication; both are sold by research suppliers for laboratory use only ^[9]. Both components are currently 503A Category 2, so they are not within FDA's enforcement-discretion policy for compounding, and both are WADA-prohibited in and out of competition for the relevant classes.

Can you get BPC-157 from a compounding pharmacy?

Currently, access is restricted. FDA placed BPC-157 in 503A Category 2 — bulk substances not within its enforcement-discretion policy — effective with the September 29, 2023 list update, so it is not eligible for routine 503A compounding while that status stands ^[9]. BPC-157 is on the July 23-24, 2026 PCAC agenda as a 503A bulks-list candidate, which is a scheduled evaluation, not a change in current status ^[10].

What is the FDA 503A status of Wolverine?

Both components are FDA 503A Category 2 bulk substances today, effective with the September 29, 2023 update, and neither is FDA-approved, so the blend has no current 503A compounding pathway ^[9]. Both BPC-157 and TB-500 are on the July 23-24, 2026 PCAC agenda as substances being considered for the 503A Bulks List — a scheduled review, not a decision ^[10].

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is FDA-approved for human use, and both are prohibited by WADA (BPC-157 under the S0 non-approved-substances category; TB-500 / Thymosin Beta-4 under prohibited peptide/growth-factor and tissue-repair categories). The blend has no approved therapeutic indication, and in 2023 FDA placed both constituents in 503A Category 2 ^[9].